Trials / Completed
CompletedNCT00075231
A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects
A Randomized, Open-Label Study Exploring a Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (planned)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether a simplified lopinavir-ritonavir based therapy will continue to keep the viral load to very low levels after initial treatment with a combination of Kaletra® (lopinavir/ritonavir) plus Combivir® (lamivudine/zidovudine).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Kaletra® (lopinavir/ritonavir) | |
| DRUG | Combivir® (lamivudine, zidovudine) | |
| DRUG | Sustiva® (efavirenz) |
Timeline
- Start date
- 2003-12-01
- First posted
- 2004-01-08
- Last updated
- 2006-10-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00075231. Inclusion in this directory is not an endorsement.